LivaNova (LIVN)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$81.92+0.89%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
Intact: The reason to own it still holds.
LivaNova grows revenue about 7-8% in 2026, as guided. Adjusted EPS is raised to $4.20-$4.30 for 2026. The company shows solid free cash flow of $160-$180 million. Its valuation is cheap versus peers with a PE of 21.65 versus 36.52.
Revenue growth could slow below 7%, hurting earnings. EPS might miss raised guidance if costs rise. The medical device market could face pricing pressure or regulatory challenges.
The price is about 11% below our fair value near $94. Analysts expect 8.3% revenue growth, close to management guidance. Our fair value is 4% above the Street median, reflecting slightly better outlook.
Breaks if: Adjusted EPS falls below $4.20 in FY26
Breaks if: Free cash flow falls below $160 million in FY26
Breaks if: YoY revenue growth falls below 7% in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
LIVN represents a durable compounder with a focus on revenue growth and adjusted earnings. The current thesis state is intact, as recent financial results remain strong within its industry.
The market appears to have priced in a neutral valuation, with LIVN being seen as cheap compared to its peers. There is a small expectations gap, indicating that the market does not anticipate significant changes in performance in the near term.
Management is on track to meet its revenue growth target of 8-9% for 2026, with recent results showing strong growth. However, adjusted free cash flow guidance has been slightly revised down, which could impact future performance.
The thesis hinges on several factors, including management's ability to raise guidance in upcoming quarters and the overall health of the job market. Additionally, performance from sector leaders could influence LIVN's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports the thesis. The company raised its revenue growth outlook to 7-8% for 2026, which is a positive signal.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: PE rises above 25 without earnings growth
Overall, LIVN's fundamentals appear solid, but the medium confidence level suggests caution. Not investment advice.